Ipsen (WBO:IPN) Accounts Receivable : €631 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Ipsen Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Ipsen's accounts receivables for the quarter that ended in Dec. 2023 was €631 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Ipsen's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 68.44.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Ipsen's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was €-16.34.

Ipsen Accounts Receivable Historical Data

The historical data trend for Ipsen's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Accounts Receivable Chart

Ipsen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

565.00

476.20

564.30

632.50

631.30

Ipsen Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Receivable	Get a 7-Day Free Trial															564.30	623.80	632.50	649.40	631.30

Ipsen Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Ipsen Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Ipsen's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	631.3	/	1683.3	*	91
=	68.44

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Ipsen's accounts receivable are only considered to be worth 75% of book value:

Ipsen's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(528.4	+	0.75 * 631.3	+	0.5 * 289.5	-	2499.1
-	0	-	-1.3)	/	82.6982
=	-16.34

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Ipsen Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Ipsen's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen (WBO:IPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (WBO:IPN) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

IPSEY:USA IPSEF:USA 0MH6:UK IPN:France I7G:Germany

Address

65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100

Website

https://www.ipsen.com

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.